Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data show encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to a press release issued by the company.
The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination. Quantum BioPharma believes this technique could enhance development of MS therapies, including its investigational candidate Lucid-MS. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the FDA in March 2026.
This milestone is significant because it moves the study closer to completion, potentially providing a new tool for visualizing myelin damage in MS patients. Current imaging methods often struggle to detect gray matter lesions, which are increasingly recognized as important in disease progression. If validated, the [¹⁸F]3F4AP tracer could improve diagnosis and monitoring of MS, as well as accelerate clinical trials for new treatments.
For the full press release, visit https://ibn.fm/4IZ0y.
The study is part of Quantum BioPharma's broader strategy to build a portfolio of innovative assets for neurodegenerative conditions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
In addition to its MS program, Quantum BioPharma has interests in alcohol misuse disorders through its stake in Unbuzzd Wellness Inc., the maker of UNBUZZD. Quantum retains 19.84% ownership (as of March 31, 2026) and receives royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% rights to develop similar products for pharmaceutical and medical uses.
The midpoint enrollment milestone brings the study—which began as a collaborative effort with Massachusetts General Hospital—closer to completion. Positive results could provide a more sensitive imaging biomarker for MS, aiding in diagnosis and treatment evaluation. This would be particularly impactful for patients with gray matter lesions, which are associated with disability progression but are often missed by conventional MRI.
Quantum BioPharma's latest news and updates are available in the company's newsroom at https://ibn.fm/QNTM. The original press release can be viewed at http://www.newmediawire.com.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. These statements are based on information available as of the date of this article, and the company undertakes no duty to update them unless required by law.
